one-carbon Therapeutics is a Swedish company specialized in targeting proteins involved in one-carbon metabolism and DNA damage and repair (DDR) as a way of inducing cancer cell death. The company is developing first-in-class inhibitors targeting MTHFD2, an oncofetal protein expressed during embryogenesis, silenced in adult cells, and then re-expressed in cancer. The lead program targets a range of cancer indications including leukemias and solid tumors with significant unmet medical needs and market potential.
Eir Ventures completes investment in one-carbon Therapeutics. Magnus Persson and Alexander Mata join the board of directors, with Magnus Persson as chairman
